Results 21 to 30 of about 10,947 (204)

Low-Cost and Portable Biosensor Based on Monitoring Impedance Changes in Aptamer-Functionalized Nanoporous Anodized Aluminum Oxide Membrane [PDF]

Micromachines
We report a low-cost, portable biosensor composed of an aptamer-functionalized nanoporous anodic aluminum oxide (NAAO) membrane and a commercial microcontroller chip-based impedance reader suitable for electrochemical impedance spectroscopy (EIS)-based ...
Nianyu Jiang, Pranav Shrotriya
doaj   +2 more sources

Efficacy of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria among children aged 2–11 years in the Asante Akim North Municipality, Ghana: a single-arm open trial [PDF]

Malar J
Henry Hanson, Kwadwo Sarfo Marfo, James Osei-Mensa, Anna Jaeger, Nimako Sarpong, Diana Nunana Tsali, Alfred Martey, A. Gyimah, Esther Placca, Morrah Oppong, Geoffrey Foli, Nana Safi Almoustapha, John Amuasi, Jürgen May, Oumou Maïga Ascofaré   +14 more
openalex   +2 more sources

Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis

PLoS ONE, 2022
Background Sub-Saharan Africa has the highest burden of malaria in the world. Artemisinin-based combination therapies (ACTs) have been the cornerstone in the efforts to reduce the global burden of malaria.
K. Marwa, Anthony Kapesa, Vito Baraka, E. Konje, Benson R. Kidenya, J. Mukonzo, E. Kamugisha, G. Swedberg   +7 more
semanticscholar   +1 more source

Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers

Malaria Journal, 2022
Artesunate–amodiaquine (ASAQ) and Artemether–lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia.
Victor S. Koko, M. Warsame, B. Vonhm, M. K. Jeuronlon, D. Ménard, Laurence Ma, Fahn Taweh, L. Tehmeh, Paye Nyansaiye, O. Pratt, Sei Parwon, Patrick Kamara, Magnus Asinya, Aaron Kollie, P. Ringwald   +14 more
semanticscholar   +1 more source

Effect of three years’ seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali

Malaria Journal, 2022
Background In 2012, seasonal malaria chemoprevention (SMC) was recommended as policy for malaria control by the World Health Organization (WHO) in areas of highly seasonal malaria transmission across the Sahel sub-region in Africa along with monitoring ...
A. Mahamar, Kelsey M. Sumner, Brandt Levitt, Betsy Freedman, Aliou Traoré, Amadou Barry, Djibrilla Issiaka, A. Dembele, Moussa B. Kanoute, Oumar Attaher, Boubacar N. Diarra, I. Sagara, A. Djimde, P. Duffy, M. Fried, S. Taylor, A. Dicko   +16 more
semanticscholar   +1 more source

Scaffold Hopping from Amodiaquine to Novel Nurr1 Agonist Chemotypes via Microscale Analogue Libraries

ChemMedChem, 2022
Several lines of evidence suggest the ligand‐sensing transcription factor Nurr1 as a promising target to treat neurodegenerative diseases. Nurr1 modulators to validate and exploit this therapeutic potential are rare, however.
Sabine Willems, Marcel Müller, Julia Ohrndorf, J. Heering, E. Proschak, D. Merk   +5 more
semanticscholar   +1 more source

Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies

British Journal of Clinical Pharmacology, 2022
Amodiaquine is a 4‐aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine.
X. H. Chan, Palang Chotsiri, Rebecca A. Capel, J. Pike, B. Hanboonkunupakarn, Sue J Lee, Maryam Hanafiah, Y. Win, Maegan Cremer, J. Kiechel, B. Ogutu, W. J. Taylor, Rebecca A. B. Burton, J. Tarning, N. White   +14 more
semanticscholar   +1 more source

Amodiaquine-Associated Asthenia: A Case Based Review and Gaps in Literature [PDF]

International Journal of Travel Medicine and Global Health, 2016
Introduction: Amodiaquine is a partner drug in the artemisinin-based combination therapy artesunate-amodiaquine. Reports of the adverse drug reaction known as amodiaquine-associated asthenia are scarce, and this adverse reaction needs to be investigated ...
Obaro Michael, Joseph Badejo, Adewale Bakre, Adebola Orimadegun, Olusegun Ademowo, Catherine Falade   +5 more
doaj   +1 more source

Development of pharmaceutically scalable inhaled anti-cancer nanotherapy – Repurposing amodiaquine for non-small cell lung cancer (NSCLC)

Materials Science and Engineering C: Materials for Biological Applications, 2020
Vineela Parvathaneni, Nishant S. Kulkarni, Gautam Chauhan, Snehal K. Shukla, Rasha S. Elbatanony, Brijeshkumar Patel, Nitesh K. Kunda, Aaron Muth, Vivek Gupta   +8 more
openalex   +3 more sources

Oral amodiaquine microparticles repurposed for the treatment of visceral leishmaniasis

Scientific African, 2022
Background: Leishmaniasis, a neglected tropical disease, is caused by parasites from the genus Leishmania and transmitted by the female phlebotamine sandfly.
Henry Nettey, Isaac Joe Erskine, Afia Antwi Mensah, Nana Kwame Ofori Gyamera, Charles Kwadwo Obuobi, Doris Kumadoh, Isaac Julius Asiedu-Gyekye, Grace Lovia Allotey-Babington   +7 more
doaj   +1 more source